| Matthew M Hand, DO | |
|
1 Elliot Way, Elliot Hospital - Pediatric Nephrology, Manchester, NH 03103-3502 | |
| (603) 669-5300 | |
| Not Available |
| Full Name | Matthew M Hand |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 35 Years |
| Location | 1 Elliot Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093743205 | NPI | - | NPPES |
| 3079126 | Medicaid | NH | |
| 297060099 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0210X | Pediatrics - Pediatric Nephrology | 1501 (Maine) | Primary |
| 2080P0210X | Pediatrics - Pediatric Nephrology | 15535 (New Hampshire) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Surfaces contaminated with SARS-CoV-2, the virus that causes COVID-19, pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and people everywhere.
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.
Even objective, automated vision testing-using a device called an autorefractor-gives variable results in patients with Down syndrome, reports a study in the May issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Trauma and critical care researchers at the University of Cincinnati (UC) have received more than $1 million from the United States Air Force in a recent set of grant awards to study how air medical evacuation affects patients, medical professionals and medical equipment.
› Verified 5 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Surfaces contaminated with SARS-CoV-2, the virus that causes COVID-19, pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and people everywhere.
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.
Even objective, automated vision testing-using a device called an autorefractor-gives variable results in patients with Down syndrome, reports a study in the May issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Trauma and critical care researchers at the University of Cincinnati (UC) have received more than $1 million from the United States Air Force in a recent set of grant awards to study how air medical evacuation affects patients, medical professionals and medical equipment.
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Surfaces contaminated with SARS-CoV-2, the virus that causes COVID-19, pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and people everywhere.
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.
Even objective, automated vision testing-using a device called an autorefractor-gives variable results in patients with Down syndrome, reports a study in the May issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Trauma and critical care researchers at the University of Cincinnati (UC) have received more than $1 million from the United States Air Force in a recent set of grant awards to study how air medical evacuation affects patients, medical professionals and medical equipment.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew M Hand, DO 1 Elliot Way, Elliot Hospital - Pediatric Nephrology, Manchester, NH 03103-3502 Ph: (603) 669-5300 | Matthew M Hand, DO 1 Elliot Way, Elliot Hospital - Pediatric Nephrology, Manchester, NH 03103-3502 Ph: (603) 669-5300 |
News Archive
Surfaces contaminated with SARS-CoV-2, the virus that causes COVID-19, pose a grave threat to the safety of healthcare workers, patients, frontline responders, military service members, cruise line passengers, hotel guests and people everywhere.
Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.
Even objective, automated vision testing-using a device called an autorefractor-gives variable results in patients with Down syndrome, reports a study in the May issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Trauma and critical care researchers at the University of Cincinnati (UC) have received more than $1 million from the United States Air Force in a recent set of grant awards to study how air medical evacuation affects patients, medical professionals and medical equipment.
› Verified 5 days ago
Dr. Rebecca Harnish Murphy, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2750 | |
Dr. Sol Rockenmacher, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Susan M Strahosky, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 275 Mammoth Rd Ste 1, Manchester, NH 03109 Phone: 603-663-3222 Fax: 603-663-3229 | |
Dr. Barbara Nan Samuels, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 275 Mammoth Rd Ste 1, Manchester, NH 03109 Phone: 036-663-8285 | |
Holly P. Mintz, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 275 Mammoth Rd, Suite #1, Manchester, NH 03109 Phone: 603-663-8350 Fax: 603-663-8399 | |
Dr. Mahendra Singh Panesar, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: Pediatric Health Associates, 275 Mammoth Road, Suite 1, Manchester, NH 03109 Phone: 603-663-8350 Fax: 603-663-8399 |